NUVATION BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.25 USD | -2.40% |
|
+0.93% | +115.23% |
| Apr. 17 | RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk | MT |
| Apr. 10 | Nuvation Bio Closes Acquisition of AnHeart Therapeutics | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 825K | Capitalization | 854M |
|---|---|---|---|---|---|
| Net income 2024 * | -101M | Net income 2025 * | -163M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,034 x |
| P/E ratio 2024 * |
-9.2
x | P/E ratio 2025 * |
-6.47
x | Employees | 51 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.17% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.40% | ||
| 1 week | +0.93% | ||
| Current month | +8.70% | ||
| 1 month | +6.56% | ||
| 3 months | +84.66% | ||
| 6 months | +151.94% | ||
| Current year | +115.23% |
1 week
3.08
3.40
1 month
2.513.43
Current year
1.434.16
1 year
0.954.16
3 years
0.9515.23
5 years
0.9515.23
10 years
0.9515.23
| Managers | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 66 | 18-03-19 |
Moses Makunje
DFI | Director of Finance/CFO | 46 | 20-06-30 |
Dong Fang Liu
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-07-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 66 | 18-03-19 |
Kim Blickenstaff
BRD | Director/Board Member | 71 | 19-07-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 20-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.25 | -2.40% | 690,376 |
| 24-05-09 | 3.33 | +3.42% | 773,359 |
| 24-05-08 | 3.22 | +0.94% | 710,144 |
| 24-05-07 | 3.19 | +0.31% | 1,542,380 |
| 24-05-06 | 3.18 | -1.24% | 1,179,252 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotes
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.25
USD
Average target price
6.6
USD
Spread / Average Target
+103.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +115.23% | 854M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- NUVB Stock
